OptimizeRx (OPRX) Chief Legal Officer Odence‑Ford Receives Award

What Happened
Marion Odence‑Ford, Chief Legal & Administrative Officer of OptimizeRx (OPRX), received a grant of 57,600 restricted stock units (RSUs) on August 20, 2026. The grant was reported on an SEC Form 4 filed August 24, 2026. The RSUs were granted at $0.00 per share (i.e., no cash paid at grant); the reported aggregate value at grant is $0 because the award is a contingent right to future shares.

Key Details

• Transaction type/code: Award/Grant (A) — 57,600 RSUs granted on 2026-08-20.
• Price at grant: $0.00 per share; aggregate reported value $0.
• Vesting: Per footnote, the RSUs vest in three equal annual installments beginning August 20, 2027 (first anniversary of grant).
• Shares owned after transaction: Not specified in this filing.
• Filing date vs transaction date: Report filed 2026-08-24 for a 2026-08-20 grant (filed 4 days after the grant); this may exceed the typical 2-business-day Section 16 reporting window.
• Remarks/footnote: Filing includes standard disclaimer that the filer is not admitting beneficial ownership or that the filing was legally required.

Context
This was an equity award (RSUs), not an open‑market purchase or sale; no cash changed hands at grant and value to the insider depends on future vesting and the stock price at distribution. RSU grants are common for compensation and retention; they do not by themselves indicate a purchase-driven bullish signal.